Fecal microbiota transplantation for gastrointestinal diseases

Keio Journal of Medicine

Volumn 63, Issue 4, 2014, Pages 69-74

  Matsuoka, Katsuyoshi ^a   Mizuno, Shinta ^a   Hayashi, Atsushi ^a,b   Hisamatsu, Tadakazu ^a   Naganuma, Makoto ^a   Kanai, Takanori ^a  

^a KEIO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b Miyarisan Pharmaceutical Co   (Japan)

Author keywords

Clostridium difficile; Crohn s disease; Gut microbiota; Transplantation; Ulcerative colitis

Indexed keywords

LOPERAMIDE; METRONIDAZOLE; PROTON PUMP INHIBITOR; VANCOMYCIN;

ABDOMINAL CRAMP; ADMINISTRATION OF DRUGS, FOOD AND CHEMICALS; AUTOIMMUNE DISEASE; CARDIOVASCULAR DISEASE; CLOSTRIDIUM DIFFICILE INFECTION; COLONOSCOPY; CONSTIPATION; DIARRHEA; DONOR SELECTION; ESOPHAGOGASTRODUODENOSCOPY; FECES MICROFLORA; GASTROINTESTINAL DISEASE; HUMAN; INFLAMMATORY BOWEL DISEASE; INTESTINE FLORA; IRRITABLE COLON; METABOLIC DISORDER; NASOGASTRIC TUBE; NONHUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); RANDOMIZED CONTROLLED TRIAL (TOPIC); RECIPIENT; RECTAL DRUG ADMINISTRATION; RECURRENT DISEASE; REVIEW; SYSTEMATIC REVIEW (TOPIC); TRANSPLANTATION; ULCERATIVE COLITIS; FECES; GASTROINTESTINAL DISEASES; MICROBIOLOGY; MICROFLORA;

FECES; GASTROINTESTINAL DISEASES; HUMANS; MICROBIOTA; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 84920541630     PISSN: 00229717     EISSN: 18801293     Source Type: Journal    
DOI: 10.2302/kjm.2014-0006-RE     Document Type: Review

References (29)

1. Blaser M, Bork P, Fraser C, Knight R, Wang J: The microbiome explored: recent insights and future challenges. Nat Rev Microbiol 2013; 11: 213–217. [Medline] [CrossRef]
2. Round JL, Mazmanian SK: The gut microbiota shapes intestinal immune responses during health and disease. Nat Rev Immunol 2009; 9: 313–323. [Medline] [CrossRef]
3. Eiseman B, Silen W, Bascom GS, Kauvar AJ: Fecal enema as an adjunct in the treatment of pseudomembranous enterocolitis. Surgery 1958; 44: 854–859. [Medline]
4. Di Bella S, Drapeau C, García-Almodóvar E, Petrosillo N: Fecal microbiota transplantation: the state of the art. Infect Dis Rep 2013; 5: 13. [Medline] [CrossRef]
5. van Nood E, Vrieze A, Nieuwdorp M, Fuentes S, Zoetendal EG, de Vos WM, Visser CE, Kuijper EJ, Bartelsman JF, Tijssen JG, Speelman P, Dijkgraaf MG, Keller JJ: Duodenal infusion of donor feces for recurrent Clostridium difficile. N Engl J Med 2013; 368: 407–415. [Medline] [CrossRef]
6. Gough E, Shaikh H, Manges AR: Systematic review of intestinal microbiota transplantation (fecal bacteriotherapy) for recurrent Clostridium difficile infection. Clin Infect Dis 2011; 53: 994–1002. [Medline] [CrossRef]
7. Smits LP, Bouter KE, de Vos WM, Borody TJ, Nieuwdorp M: Therapeutic potential of fecal microbiota transplantation. Gastroenterology 2013; 145: 946–953. [Medline] [CrossRef]
8. Hamilton MJ, Weingarden AR, Sadowsky MJ, Khoruts A: Standardized frozen preparation for transplantation of fecal microbiota for recurrent Clostridium difficile infection. Am J Gastroenterol 2012; 107: 761–767. [Medline] [CrossRef]
9. Anderson JL, Edney RJ, Whelan K: Systematic review: faecal microbiota transplantation in the management of inflammatory bowel disease. Aliment Pharmacol Ther 2012; 36: 503–516. [Medline] [CrossRef]
10. Angelberger S, Reinisch W, Makristathis A, Lichtenberger C, Dejaco C, Papay P, Novacek G, Trauner M, Loy A, Berry D: Temporal bacterial community dynamics vary among ulcerative colitis patients after fecal microbiota transplantation. Am J Gastroenterol 2013; 108: 1620–1630. [Medline] [CrossRef]
11. Schwartz M, Gluck M, Koon S: Norovirus gastroenteritis after fecal microbiota transplantation for treatment of Clostridium difficile infection despite asymptomatic donors and lack of sick contacts. Am J Gastroenterol 2013; 108: 1367. [Medline] [CrossRef]
12. Brandt LJ, Aroniadis OC, Mellow M, Kanatzar A, Kelly C, Park T, Stollman N, Rohlke F, Surawicz C: Long-term follow-up of colonoscopic fecal microbiota transplant for recurrent Clostridium difficile infection. Am J Gastroenterol 2012; 107: 1079–1087. [Medline] [CrossRef]
13. Leffler DA, Lamont JT: Treatment of Clostridium difficile-associated disease. Gastroenterology 2009; 136: 1899–1912. [Medline] [CrossRef]
14. Kelly CR, de Leon L, Jasutkar N: Fecal microbiota transplantation for relapsing Clostridium difficile infection in 26 patients: methodology and results. J Clin Gastroenterol 2012; 46: 145–149. [Medline] [CrossRef]
15. Surawicz CM, Brandt LJ, Binion DG, Ananthakrishnan AN, Curry SR, Gilligan PH, McFarland LV, Mellow M, Zuckerbraun BS: Guidelines for diagnosis, treatment, and prevention of Clostridium difficile infections. Am J Gastroenterol 2013; 108: 478–498, quiz 499. [Medline] [CrossRef]
16. Kelly CR, Kunde SS, Khoruts A: Guidance on preparing an investigational new drug application for fecal microbiota transplantation studies. Clin Gastroenterol Hepatol 2014; 12: 283–288. [Medline] [CrossRef]
17. Sartor RB: Microbial influences in inflammatory bowel diseases. Gastroenterology 2008; 134: 577–594. [Medline] [CrossRef]
18. Takaishi H, Matsuki T, Nakazawa A, Takada T, Kado S, Asahara T, Kamada N, Sakuraba A, Yajima T, Higuchi H, Inoue N, Ogata H, Iwao Y, Nomoto K, Tanaka R, Hibi T: Imbalance in intestinal microflora constitution could be involved in the pathogenesis of inflammatory bowel disease. Int J Med Microbiol 2008; 298: 463–472.[Medline] [CrossRef]
19. Ott SJ, Plamondon S, Hart A, Begun A, Rehman A, Kamm MA, Schreiber S: Dynamics of the mucosa-associated flora in ulcerative colitis patients during remission and clinical relapse. J Clin Microbiol 2008; 46: 3510–3513.[Medline] [CrossRef]
20. Bennet JD, Brinkman M: Treatment of ulcerative colitis by implantation of normal colonic flora. Lancet 1989; 1: 164.[Medline] [CrossRef]
21. Borody TJ, Warren EF, Leis S, Surace R, Ashman O: Treatment of ulcerative colitis using fecal bacteriotherapy. J Clin Gastroenterol 2003; 37: 42–47.[Medline] [CrossRef]
22. Kump PK, Gröchenig HP, Lackner S, Trajanoski S, Reicht G, Hoffmann KM, Deutschmann A, Wenzl HH, Petritsch W, Krejs GJ, Gorkiewicz G, Högenauer C: Alteration of intestinal dysbiosis by fecal microbiota transplantation does not induce remission in patients with chronic active ulcerative colitis. Inflamm Bowel Dis 2013; 19: 2155–2165.[Medline] [CrossRef]
23. Kunde S, Pham A, Bonczyk S, Crumb T, Duba M, Conrad H, Cloney D, Kugathasan S: Safety, tolerability, and clinical response after fecal transplantation in children and young adults with ulcerative colitis. J Pediatr Gastroenterol Nutr 2013; 56: 597–601.[Medline] [CrossRef]
24. Quera R, Espinoza R, Estay C, Rivera D: Bacteremia as an adverse event of fecal microbiota transplantation in a patient with Crohns disease and recurrent Clostridium difficile infection. J Crohns Colitis 2014; 8: 252–253.[Medline] [CrossRef]
25. Gordon H, Harbord M: A patient with severe Crohns colitis responds to faecal microbiota transplantation. J Crohns Colitis 2014; 8: 256–257.[Medline] [CrossRef]
26. Borody TJ, Paramsothy S, Agrawal G: Fecal microbiota transplantation: indications, methods, evidence, and future directions. Curr Gastroenterol Rep 2013; 15: 337.[Medline] [CrossRef]
27. Jeffery IB, O’Toole PW, Öhman L, Claesson MJ, Deane J, Quigley EM, Simrén M: An irritable bowel syndrome subtype defined by species-specific alterations in faecal microbiota. Gut 2012; 61: 997–1006.[Medline] [CrossRef]
28. Vrieze A, Van Nood E, Holleman F, Salojärvi J, Kootte RS, Bartelsman JF, Dallinga-Thie GM, Ackermans MT, Serlie MJ, Oozeer R, Derrien M, Druesne A, Van Hylckama Vlieg JE, Bloks VW, Groen AK, Heilig HG, Zoetendal EG, Stroes ES, de Vos WM, Hoekstra JB, Nieuwdorp M: Transfer of intestinal microbiota from lean donors increases insulin sensitivity in individuals with metabolic syndrome. Gastroenterology 2012; 143: 913–916, 7.[Medline] [CrossRef]
29. Udayappan SD, Hartstra AV, Dallinga-Thie GM, Nieuwdorp M: Intestinal microbiota and faecal transplantation as treatment modality for insulin resistance and type 2 diabetes mellitus. Clin Exp Immunol 2014; 177: 24–29.[Medline] [CrossRef]